2025
Low and high air temperature and cardiovascular risk
Ni W, Areal A, Lechner K, Breitner S, Zhang S, Woeckel M, Slesinski S, Nikolaou N, Dallavalle M, Schikowski T, Schneider A. Low and high air temperature and cardiovascular risk. Atherosclerosis 2025, 406: 119238. PMID: 40383648, DOI: 10.1016/j.atherosclerosis.2025.119238.Peer-Reviewed Original ResearchConceptsCardiovascular diseaseArea-level factorsRisk factorsIndividual-level measuresPre-existing cardiovascular diseasePopulation healthCardiovascular healthCardiovascular mortalityPublic healthHealthJ-shapedEpidemiological dataCardiovascular riskBiological plausibilityRiskAir pollutionAssociationPopulationMortalityClimate changeExtremitiesIndividual-Social dimensions of climate changeDiseaseDimensions of climate changeAlcohol use, heavy episodic drinking, and associated cardiovascular risk in Guyana
Motilal M, Gobin R, Khan R, Maharaj R. Alcohol use, heavy episodic drinking, and associated cardiovascular risk in Guyana. BULL PAN AM HEALTH ORGAN 2025, 49: 1. PMID: 40206567, PMCID: PMC11980521, DOI: 10.26633/rpsp.2025.30.Peer-Reviewed Original ResearchHeavy episodic drinkingAlcohol useWorld Health OrganizationSecondary analysisIndo-GuyaneseCardiovascular riskSecondary analysis of dataRisk factor surveyRisk of heavy episodic drinkingEpisodic drinkingPublic health interventionsOdds of alcohol useOdds of heavy episodic drinkingElevated blood pressureCardiovascular risk factorsBinary logistic regressionFactor surveyMaximum educational levelHealth interventionsYoung malesLinear regression modelsElevated triglyceridesDescriptive statisticsEducation levelAdjusted modelsThe Molecular Basis of Polycystic Ovary Syndrome and Its Cardiometabolic Correlates: Exploring the Intersection and Its Clinical Implications—A Narrative Review
Mahabamunuge J, Sekula N, Lepore C, Kudrimoti M, Upadhyay A, Alshowaikh K, Li H, Seifer D, AlAshqar A. The Molecular Basis of Polycystic Ovary Syndrome and Its Cardiometabolic Correlates: Exploring the Intersection and Its Clinical Implications—A Narrative Review. Biomedicines 2025, 13: 709. PMID: 40149685, PMCID: PMC11940587, DOI: 10.3390/biomedicines13030709.Peer-Reviewed Original ResearchPolycystic ovary syndromeType 2 diabetes mellitusCardiometabolic morbidityIncreased cardiovascular riskDevelopment of hypertensionCardiovascular risk factorsNarrative reviewPotential clinical implicationsAndrogen excessEndothelial dysfunctionCardiovascular riskClinical conditionsPredisposed individualsTherapeutic strategiesAdipokine secretionRisk factorsInsulin resistanceCardiometabolic diseasesCardiovascular diseaseClinical implicationsMorbidityMellitusSyndromeMolecular mechanismsDiseaseOlezarsen in patients with hypertriglyceridemia at high cardiovascular risk: Rationale and design of the Essence–TIMI 73b trial
Bergmark B, Marston N, Prohaska T, Alexander V, Zimerman A, Moura F, Kang Y, Murphy S, Zhang S, Lu M, Karwatowska-Prokopczuk E, Tsimikas S, Giugliano R, Sabatine M. Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk: Rationale and design of the Essence–TIMI 73b trial. American Heart Journal 2025, 286: 116-124. PMID: 40081744, PMCID: PMC12065083, DOI: 10.1016/j.ahj.2025.02.022.Peer-Reviewed Original ResearchMeSH KeywordsAgedApolipoprotein C-IIICardiovascular DiseasesClinical Trials, Phase III as TopicComputed Tomography AngiographyCoronary AngiographyDouble-Blind MethodFemaleHeart Disease Risk FactorsHumansHypertriglyceridemiaMaleMiddle AgedOligonucleotidesOligonucleotides, AntisenseRandomized Controlled Trials as TopicTriglyceridesConceptsCoronary Computed Tomography AngiographyCardiovascular riskTriglyceride levelsModerate hypertriglyceridemiaBaseline coronary computed tomography angiographyPlacebo-controlled phase 3 trialClearance of triglyceride-rich lipoproteinsApoC-IIIBaseline triglyceride levelsBaseline to 6 monthsLipid-Lowering TherapyAntisense oligonucleotidesNoncalcified coronary plaquesPhase 3 trialComputed tomography angiographyLowering triglyceride levelsIncreased cardiovascular riskElevated cardiovascular riskReduce cardiovascular riskAtherosclerotic cardiovascular diseaseTriglyceride-rich lipoproteinsPotential therapeutic strategyPooled placeboApolipoprotein C-IIIDouble-blindEffects of psychedelics on opioid use disorder: a scoping review of preclinical studies
Pulido-Saavedra A, Oliva H, Prudente T, Kitaneh R, Nunes E, Fogg C, Funaro M, Weleff J, Nia A, Angarita G. Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies. Cellular And Molecular Life Sciences 2025, 82: 49. PMID: 39833376, PMCID: PMC11747050, DOI: 10.1007/s00018-024-05519-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsOpioid use disorderUse disorderPreclinical studiesClinical studiesReview of preclinical studiesConditioned place preferenceOpioid Self-AdministrationEffects of psychedelicsPreclinical in vivo studiesOpioid use disorder treatmentFrequency of administrationPlace preferencePotential therapeutic effectsSelf-AdministrationWithdrawal symptomsPreclinical findingsMechanism of actionSafety profilePain studiesPsychedelicsMethodological quality assessmentClinical evidenceCardiovascular riskOpioidWeb of ScienceChapter 14 Impact of androgens on cardiovascular risk in women with polycystic ovary syndrome and transgender men
Stachenfeld N, Alexander L, Bender J, Weinzimer S, Pal L, Reckelhoff J. Chapter 14 Impact of androgens on cardiovascular risk in women with polycystic ovary syndrome and transgender men. 2025, 279-293. DOI: 10.1016/b978-0-443-22266-5.00014-8.Peer-Reviewed Original ResearchGender-affirming hormone therapyAE-PCOSTransgender menPolycystic ovary syndromeFemale endocrinopathyHigher androgenLong-term consequencesMild hypertensionEndothelial dysfunctionAssociated with endothelial dysfunctionIncreased risk of endothelial dysfunctionRisk of endothelial dysfunctionMenImpact of androgensHyperandrogenemiaHormone therapyHigher androgen levelsInfertilityAndrogen levelsCardiovascular riskVascular systemIncreased riskMetabolic dysfunctionVascular functionCardiovascular disease
2024
Nonlinearity of the inverse relationship between high-density lipoprotein (HDL) cholesterol and incident cardiovascular risk: Is it time to revisit the “HDL hypothesis”?
Hashem C, Altin S, Guyton J, Boden W. Nonlinearity of the inverse relationship between high-density lipoprotein (HDL) cholesterol and incident cardiovascular risk: Is it time to revisit the “HDL hypothesis”? Journal Of Clinical Lipidology 2024, 19: 238-246. PMID: 39934033, DOI: 10.1016/j.jacl.2024.12.009.Peer-Reviewed Original ResearchLow HDL-CHDL-C levelsHDL-CAssociated with atherosclerotic cardiovascular diseaseRandomized Controlled TrialsLow levels of high-density lipoprotein cholesterolLow HDL-C levelsLevels of high-density lipoprotein cholesterolIncident cardiovascular riskLevels of HDL-CReduce ASCVD eventsHigh-density lipoprotein cholesterolOptimal risk stratificationHigh-density lipoprotein (HDLStatin-based therapyHDL hypothesisAtherosclerotic cardiovascular diseaseLipoprotein (HDLRisk-enhancing factorsIncident cardiovascular eventsCholesterol guidelinesRisk stratificationCardiovascular eventsLipoprotein cholesterolCardiovascular riskSoutheAsTern eUrope microciRculATION (SATURATION) registry - Design and rationale
Odanovic N, Tsioufis K, Dimitriadis K, Sakalidis A, Papafaklis M, Davlouros P, Ivanov I, Cankovic M, Kalogeropoulos A, Hamilos M, Sideras E, Konigstein M, Zornitzki L, Kovarnik T, Ruzsa Z, Piroth Z, Zdravkovic M, Mehmedbegovic Z, Miovski Z, Jurin H, Kanovsky J, Regev E, Shah S, Ilic I, investigators S. SoutheAsTern eUrope microciRculATION (SATURATION) registry - Design and rationale. Cardiovascular Revascularization Medicine 2024 PMID: 39672766, DOI: 10.1016/j.carrev.2024.11.012.Peer-Reviewed Original ResearchSeattle Angina QuestionnairePatient-centered outcomesEQ-5D-5LQuality of lifeAngina QuestionnaireCoronary function testingInvasive physiologic evaluationMajor adverse cardiovascular eventsStages of coronary artery diseaseCoronary microvascular dysfunctionInvasive coronary physiological assessmentAdverse cardiovascular eventsPotential interventionsSigns of ischemiaCoronary artery diseaseCardiac catheterization labEvaluation of microcirculationDegree of coronary atherosclerosisRegistryCoronary physiology assessmentClinical practiceSymptomatic patientsCardiovascular riskPatient selectionMicrovascular dysfunctionAdverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors
Kwan J, Shen M, Akhlaghi N, Hu J, Mora R, Cross J, Jiang M, Mankbadi M, Wang P, Zaman S, Lee S, Im Y, Feher A, Liu Y, S. S, Tao W, Wei W, Baldassarre L. Adverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors. PLOS ONE 2024, 19: e0314555. PMID: 39621799, PMCID: PMC11611253, DOI: 10.1371/journal.pone.0314555.Peer-Reviewed Original ResearchConceptsAdverse cardiovascular eventsICI therapyCardiac magnetic resonanceIncreased risk of mortalityICI initiationIncreased riskRisk of mortalityCentral nervous systemVentricular dysfunctionCancer patients treated with ICIsCardiovascular eventsLeft ventricular late gadolinium enhancementMortality benefitCardiovascular riskAbnormal left ventricular ejection fractionPatients treated with ICIsLeft ventricular ejection fractionCentral nervous system malignanciesRisk of adverse cardiovascular eventsImmune checkpoint inhibitorsRight ventricular dysfunctionGlobal longitudinal strainVentricular ejection fractionLeft ventricular dysfunctionMultimodality cardiac imagingTreating Migraine Patients With Cardiovascular Risks
Wang K, Sico J. Treating Migraine Patients With Cardiovascular Risks. Neurology 2024, 103: e210196. PMID: 39621947, DOI: 10.1212/wnl.0000000000210196.Peer-Reviewed Original ResearchNonaspirin nonsteroidal anti-inflammatory drugsCardiovascular safety profileSafety profileCardiovascular eventsCardiovascular riskIncreased riskIncreased risk of ischemic eventsRisk of ischemic eventsNonsteroidal anti-inflammatory drugsExclusion of patientsAdverse cardiovascular eventsMyocardial infractionRisk of acute cardiovascular eventsEffective acute treatmentTreat migraine patientsRisk of myocardial infractionCOX-2 inhibitorsAnti-inflammatory drugsAcute cardiovascular eventsMigraine patientsAcute treatmentIschemic eventsManaging cardiovascular riskRandomized trialsCOX-2Sex-specific associations between 10-year cardiovascular risk, clinical symptoms and cognitive impairments in schizophrenia
Jin X, Lu C, Liu N, Li Y, Dong Y, Wang X, Li S, Li J. Sex-specific associations between 10-year cardiovascular risk, clinical symptoms and cognitive impairments in schizophrenia. Journal Of Neural Transmission 2024, 132: 313-322. PMID: 39387913, DOI: 10.1007/s00702-024-02842-7.Peer-Reviewed Original ResearchPositive and Negative Syndrome ScaleRepeatable Battery for the Assessment of Neuropsychological StatusPsychiatric symptomsNegative symptomsCognitive functionSex differencesAssessment of Neuropsychological StatusPANSS total scoreNegative Syndrome ScaleFramingham risk scoreSignificant sex differencesSyndrome ScalePsychopathology scoresImmediate memoryNeuropsychological StatusCardiovascular riskSCZTotal scoreCognitive impairmentCardiovascular diseaseSex-specific associationsFasting venous blood samplesHigher Framingham risk scoreGlycolipid metabolism indexesSymptomsIs There an Association Between Endometriosis, Early Menopause, and Cardiovascular Disease?
Younis J, Taylor H. Is There an Association Between Endometriosis, Early Menopause, and Cardiovascular Disease? The Journal Of Clinical Endocrinology & Metabolism 2024, 109: e1946-e1949. PMID: 39083665, DOI: 10.1210/clinem/dgae508.Peer-Reviewed Original ResearchEarly menopauseEndometriotic cystectomyNatural menopauseCardiovascular riskCardiovascular diseaseEndometriosis-associated pelvic painIncreased risk of cardiovascular diseaseLaparoscopically diagnosed endometriosisRisk of cardiovascular diseaseEarly natural menopauseLarge-scale cohort studyPelvic painOvarian reserveBilateral casesMenopause onsetMultiple surgeriesEndometriosisCohort studyHazard ratioIncreased riskMenopauseCystectomyRisk factorsEstimates of associationConfounding factorsPathophysiology, Diagnosis, Prognosis, and Prevention of Poststroke Epilepsy
Tanaka T, Ihara M, Fukuma K, Mishra N, Koepp M, Guekht A, Ikeda A. Pathophysiology, Diagnosis, Prognosis, and Prevention of Poststroke Epilepsy. Neurology 2024, 102: e209450. PMID: 38759128, PMCID: PMC11175639, DOI: 10.1212/wnl.0000000000209450.Peer-Reviewed Original ResearchConceptsPoststroke epileptogenesisPoststroke epilepsyStroke survivorsAssociated with high mortalityAttention of health policymakersBurden of stroke worldwideDiagnostic work-upRisk of seizuresRisk-scoring modelSurrogate outcome measuresCortical superficial siderosisPrevention of seizuresSecondary prevention of seizuresPrimary prophylaxisConcomitant medicationsEEG findingsAcute stroke treatmentRecurrence riskSeizure prophylaxisSuperficial siderosisAntiseizure medicationsCardiovascular riskTreatment strategiesEnrolling patientsTissue-based approachSubclinical Atherosclerosis to Guide Treatment in Dyslipidemia and Diabetes Mellitus
Mszar R, Katz M, Grandhi G, Osei A, Gallo A, Blaha M. Subclinical Atherosclerosis to Guide Treatment in Dyslipidemia and Diabetes Mellitus. Current Atherosclerosis Reports 2024, 26: 217-230. PMID: 38662272, DOI: 10.1007/s11883-024-01202-w.Peer-Reviewed Original ResearchConceptsCoronary artery calciumType 2 diabetes mellitusAtherosclerotic cardiovascular diseaseDiabetes mellitusCardiovascular riskAtherosclerotic burdenIncreased CACComputed tomography coronary angiographyRisk of cardiovascular eventsIncreased risk of atherosclerotic cardiovascular diseaseLow-density lipoprotein cholesterolRisk of atherosclerotic cardiovascular diseaseMarkers of dyslipidemiaThoracic aorta calcificationCoronary Artery Calcium TestingStratify cardiovascular riskPrimary prevention settingSubclinical atherosclerotic burdenAorta calcificationCardiovascular disease preventionAssessment of subclinical atherosclerosisPrimary hypercholesterolemiaStatin therapyCoronary angiographyArtery calciumOlezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
Bergmark B, Marston N, Prohaska T, Alexander V, Zimerman A, Moura F, Murphy S, Goodrich E, Zhang S, Gaudet D, Karwatowska-Prokopczuk E, Tsimikas S, Giugliano R, Sabatine M. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. New England Journal Of Medicine 2024, 390: 1770-1780. PMID: 38587249, DOI: 10.1056/nejmoa2402309.Peer-Reviewed Original ResearchConceptsNon-HDL cholesterolElevated cardiovascular riskLevels of triglyceridesTriglyceride levelsCardiovascular riskModerate hypertriglyceridemiaApolipoprotein BAdverse eventsNon-high-density lipoprotein (HDL) cholesterolLow-density lipoprotein (LDL) cholesterolBaseline to 6 monthsMedian triglyceride levelsRisk of adverse eventsLDL cholesterol levelsHigh cardiovascular riskTriglyceride-rich lipoproteinsApolipoprotein C-IIISevere hypertriglyceridemiaMedian ageTriglyceride loweringPlatelet abnormalitiesNo significant changesPlaceboPhase 2bPrimary outcomeEffectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk
McCoy R, Herrin J, Swarna K, Deng Y, Kent D, Ross J, Umpierrez G, Galindo R, Crown W, Borah B, Montori V, Brito J, Neumiller J, Mickelson M, Polley E. Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk. Nature Cardiovascular Research 2024, 3: 431-440. PMID: 38846711, PMCID: PMC11156225, DOI: 10.1038/s44161-024-00453-9.Peer-Reviewed Original ResearchAdverse cardiovascular eventsGlucose-lowering medicationsType 2 diabetesCardiovascular diseaseGLP-1RACardiovascular eventsGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsPeptidase-4 inhibitorsRetrospective cohort studyCardiovascular disease risk reductionGlucose-lowering agentsModerate cardiovascular riskCardiovascular risk reductionReceptor agonistsEffects of glucose-lowering medicationsRisk reductionCardiovascular riskCohort studyCardiovascular outcomesHigh riskBaseline riskModerate riskRNA Interference-based Therapies for the Reduction of Cardiovascular Risk
Nazarenko N, Seo J, Nagraj S, Palaiodimos L, Kokkinidis D. RNA Interference-based Therapies for the Reduction of Cardiovascular Risk. Current Molecular Pharmacology 2024, 17: e18761429264553. PMID: 38449067, DOI: 10.2174/0118761429264553231204115314.Peer-Reviewed Original ResearchLDL-C levelsLDL-CReduction of cardiovascular riskRNA interference-based therapiesSignificant cardiovascular eventsLDL-C level reductionRisk of cardiovascular diseaseCases of coronary artery diseaseNon-modifiable risk factorsCoronary artery diseasePrevalent risk factorIncidence of CVDLowering lipid levelsRisk factors of heart diseaseCardiovascular eventsFactors of heart diseaseMortality benefitCardiovascular riskArtery diseaseRisk factorsHeart diseaseLipid levelsCardiovascular diseasePrevent 2Lifestyle factorsWhat Is the Role of Minimally Invasive Liver Surgery in Treating Patients with Hepatocellular Carcinoma on Cirrhosis?
Vitale A, Angelico R, Sensi B, Lai Q, Kauffmann E, Scalera I, Serenari M, Ginesini M, Romano P, Furlanetto A, D’Amico F. What Is the Role of Minimally Invasive Liver Surgery in Treating Patients with Hepatocellular Carcinoma on Cirrhosis? Cancers 2024, 16: 966. PMID: 38473327, PMCID: PMC10930835, DOI: 10.3390/cancers16050966.Peer-Reviewed Original ResearchMinimally invasive liver surgeryOpen surgeryLiver surgerySignificant cardiovascular riskTrans-arterial approachResection outcomesLaparoscopic ablationResected casesLiver transplantationTreated patientsHepatocellular carcinomaEfficacious therapyCardiovascular riskSurgeryPatientsNarrative reviewTreatment hierarchyCurative techniqueHCCResectionCarcinomaCirrhosisTransplantationTherapyCardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)
Green J, Everett B, Ghosh A, Younes N, Krause-Steinrauf H, Barzilay J, Desouza C, Inzucchi S, Pokharel Y, Schade D, Scrymgeour A, Tan M, Utzschneider K, Mudaliar S, Crandall J, McKee M, Behringer-Massera S, Brown-Friday J, Xhori E, Ballentine-Cargill K, Duran S, Estrella H, Gonzalez de la Torre S, Lukin J, Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Raines T, Boers J, Costello J, Maher-Albertelli M, Mungara R, Savoye L, White C, Gullett C, Holloway L, Morehead F, Person S, Sibymon M, Tanukonda S, Adams C, Ross A, Balasubramanyam A, Gaba R, Gonzalez Hattery E, Ideozu A, Jimenez J, Montes G, Wright C, Hollander P, Roe E, Jackson A, Smiley A, Burt P, Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Sayyed Kassem L, Sood A, Tiktin M, Kulow T, Newman C, Stancil K, Cramer B, Iacoboni J, Kononets M, Sanders C, Tucker L, Werner A, Maxwell A, McPhee G, Patel C, Colosimo L, Krol A, Goland R, Pring J, Alfano L, Kringas P, Hausheer C, Tejada J, Gumpel K, Kirpitch A, Schneier H, AbouAssi H, Chatterjee R, Feinglos M, English Jones J, Khan S, Kimpel J, Zimmer R, Furst M, Satterwhite B, Thacker C, Evans Kreider K, Mariash C, Mather K, Ismail H, Lteif A, Mullen M, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Aguillar D, Howard D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Yang S, Kleeberger K, Passi R, Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow S, Bays K, Berame K, Cook J, Ghioni D, Gluth J, Schell K, Criscola J, Friason C, Jones S, Nazarov S, Rassouli N, Puttnam R, Ojoawo B, Nelson R, Curtis M, Hollis B, Sanders-Jones C, Stokes K, El-Haqq Z, Kolli A, Tran T, Wexler D, Larkin M, Meigs J, Chambers B, Dushkin A, Rocchio G, Yepes M, Steiner B, Dulin H, Cayford M, Chu K, DeManbey A, Hillard M, Martin K, Thangthaeng N, Gurry L, Kochis R, Raymond E, Ripley V, Stevens C, Park J, Aroda V, Ghazi A, Magee M, Ressing A, Loveland A, Hamm M, Hurtado M, Kuhn A, Leger J, Manandhar L, Mwicigi F, Sanchez O, Young T, Garg R, Lagari-Libhaber V, Florez H, Valencia W, Marks J, Casula S, Oropesa-Gonzalez L, Hue L, Cuadot A, Nieto-Martinez R, Riccio Veliz A, Gutt M, Kendal Y, Veciana B, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague C, Yamashita D, Cady N, Rivera-Eschright N, Kirchhoff P, Morales Gomez B, Adducci J, Goncharova A, Hox S, Petrovitch H, Matwichyna M, Jenkins V, Broadwater L, Ishii R, Bermudez N, Hsia D, Cefalu W, Greenway F, Waguespack C, King E, Fry G, Dragg A, Gildersleeve B, Arceneaux J, Haynes N, Thomassie A, Pavlionis M, Bourgeois B, Hazlett C, Henry R, Boeder S, Pettus J, Diaz E, Garcia-Acosta D, Maggs S, DeLue C, Stallings A, Castro E, Hernandez S, Krakoff J, Curtis J, Killean T, Khalid M, Joshevama E, Diaz E, Martin D, Tsingine K, Karshner T, Albu J, Pi-Sunyer F, Frances S, Maggio C, Ellis E, Bastawrose J, Gong X, Banerji M, August P, Lee M, Lorber D, Brown N, Josephson D, Thomas L, Tsovian M, Cherian A, Jacobson M, Mishko M, Kirkman M, Buse J, Diner J, Dostou J, Machineni S, Young L, Bergamo K, Goley A, Kerr J, Largay J, Guarda S, Cuffee J, Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, Fuller G, Garvey W, Cherrington A, Dyer D, Lawson M, Griffith O, Agne A, McCullars S, Cohen R, Craig J, Rogge M, Burton K, Kersey K, Wilson C, Lipp S, Vonder Meulen M, Adkins C, Onadeko T, Rasouli N, Baker C, Schroeder E, Razzaghi M, Lyon C, Penaloza R, Underkofler C, Lorch R, Douglass S, Steiner S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, Herman W, Pop-Busui R, Martin C, Waltje A, Katona A, Goodhall L, Eggleston R, Kuo S, Bojescu S, Bule S, Kessler N, LaSalle E, Whitley K, Seaquist E, Bantle A, Harindhanavudhi T, Kumar A, Redmon B, Bantle J, Coe M, Mech M, Taddese A, Lesne L, Smith S, Kuechenmeister L, Shivaswamy V, Burbach S, Rodriguez M, Seipel K, Alfred A, Morales A, Eggert J, Lord G, Taylor W, Tillson R, Adolphe A, Burge M, Duran-Valdez E, Martinez J, Bancroft A, Kunkel S, Ali Jamaleddin Ahmad F, Hernandez McGinnis D, Pucchetti B, Scripsick E, Zamorano A, DeFronzo R, Cersosimo E, Abdul-Ghani M, Triplitt C, Juarez D, Mullen M, Garza R, Verastiqui H, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Jordan L, Sao S, Morton L, Smith O, Osornio Walker L, Schnurr-Breen L, Ayala R, Kreymer R, Sturgess D, Kahn S, Alarcon-Casas Wright L, Boyko E, Tsai E, Trence D, Trikudanathan S, Fattaleh B, Montgomery B, Atkinson K, Kozedub A, Concepcion T, Moak C, Prikhodko N, Rhothisen S, Elasy T, Martin S, Shackelford L, Goidel R, Hinkle N, Lovell C, Myers J, Lipps Hogan J, McGill J, Salam M, Schweiger T, Kissel S, Recklein C, Clifton M, Tamborlane W, Camp A, Gulanski B, Pham K, Alguard M, Gatcomb P, Lessard K, Perez M, Iannone L, Magenheimer E, Montosa A, Cefalu W, Fradkin J, Burch H, Bremer A, Nathan D, Lachin J, Buse J, Kahn S, Larkin M, Tiktin M, Wexler D, Burch H, Bremer A, Lachin J, Bebu I, Butera N, Buys C, Fagan A, Gao Y, Gramzinski M, Hall S, Kazemi E, Legowski E, Liu H, Suratt C, Tripputi M, Arey A, Backman M, Bethepu J, Lund C, Mangat Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, Seegmiller J, Saenger A, Arends V, Gabrielson D, Conner T, Warren S, Day J, Huminik J, Soliman E, Zhang Z, Campbell C, Hu J, Keasler L, Hensley S, Li Y, Herman W, Kuo S, Martin C, Waltje A, Mihalcea R, Min D, Perez-Rosas V, Prosser L, Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Assuras S, Groessl E, Sakha F, Chong H, Hillery N, Abdouch I, Bahtiyar G, Brantley P, Broyles F, Canaris G, Copeland P, Craine J, Fein W, Gliwa A, Hope L, Lee M, Meiners R, Meiners V, O’Neal H, Park J, Sacerdote A, Sledge Jr E, Soni L, Steppel-Reznik J, Turchin A. Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study). Circulation 2024, 149: 993-1003. PMID: 38344820, PMCID: PMC10978227, DOI: 10.1161/circulationaha.123.066604.Peer-Reviewed Original ResearchConceptsType 2 diabetesGlucose-lowering medicationsCardiovascular diseaseMACE-4MACE-3Baseline prevalence of cardiovascular diseasesCardiovascular outcomesPrevalence of cardiovascular diseaseCohort of adultsContemporary cohort of adultsCox proportional hazards modelsEffects of glucose-lowering medicationsLow cardiovascular riskProportional hazards modelType 2 diabetes durationRisk of cardiovascular eventsPrespecified outcomesHazards modelCardiovascular riskInvestigated cardiovascular outcomesLow riskLiraglutide-treated groupStatistically significant differenceHeart failureCumulative incidenceAI-derived epicardial fat measurements improve cardiovascular risk prediction from myocardial perfusion imaging
Miller R, Shanbhag A, Killekar A, Lemley M, Bednarski B, Van Kriekinge S, Kavanagh P, Feher A, Miller E, Einstein A, Ruddy T, Liang J, Builoff V, Berman D, Dey D, Slomka P. AI-derived epicardial fat measurements improve cardiovascular risk prediction from myocardial perfusion imaging. Npj Digital Medicine 2024, 7: 24. PMID: 38310123, PMCID: PMC10838293, DOI: 10.1038/s41746-024-01020-z.Peer-Reviewed Original ResearchEpicardial adipose tissueMyocardial infarctionPerfusion imagingEpicardial adipose tissue measurementsEpicardial adipose tissue volumeEAT attenuationMedian Follow-UpIncreased risk of deathEpicardial fat measurementMyocardial perfusion imagingAssociated with cardiovascular riskCoronary artery diseaseAssociated with deathEating measuresRisk of deathEAT volumeLow-dosePrognostic insightsFollow-upCardiovascular riskCardiovascular risk predictionUngated CTArtery diseaseIncreased riskCardiac silhouette
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply